UNSPSC 51432702: Zabicipril

This classification denotes an ace inhibitor with the molecular formula C23H32N2O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 475035SS4C, chemically known as (3s)-2-((2s)-n-((1s)-1-carboxy-3-phenylpropyl)alanyl)-2-azabicyclo(2.2.2)octane-3-carboxylic acid, 1-ethyl ester but generally known as zabicipril, which bears US NIH Compound Identifier 71262. European Medicines Agency schedules Zabicipril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00125MIG.

UNSPSC 51432702 Zabicipril, a Commodity code, does not align with the state and local procurement activity tagged under it. The single recent opportunity on record is the City of Tampa's April 2026 sealed-bid solicitation for Advanced Life Support Medications (26P00188) for Tampa Fire Rescue, which calls for supply of Labetalol HCI, Epinephrine, Adenosine, and Diltiazem vials—emergency-response pharmaceuticals used in pre-hospital and acute-care settings. The code nominally designates a single pharmaceutical ingredient (Zabicipril, an ACE inhibitor antihypertensive), yet the Tampa bid specifies four different cardiac and vasopressor agents with no overlap to the code's stated drug. This mismatch suggests either a tagging error in the state database or a misalignment between procurement taxonomy and actual acquisition scope under this code number.

The Tampa procurement is the only recent state or local opportunity identifiable under UNSPSC 51432702. The solicitation targets medication suppliers capable of meeting OSHA Hazard Communication Standards, maintaining nine-month-minimum shelf life, and delivering within ten calendar days. The estimated contract value is $40,000.00, with a one-year base term plus two optional one-year renewals and three unilateral 30-day extensions. Tampa applied a Small Local Business Enterprise sheltered-market designation with a 5 percent bid discount capped at $10,000. The response deadline was April 8, 2026. Without additional recent opportunities under this code, market activity appears minimal to nonexistent; business development professionals should verify whether this code number correctly reflects their target pharmaceutical commodities or whether related codes under the broader pharmaceutical family better align with state and local emergency-response medication procurement.